These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. ExPPNing how acetylcholine improves gait in Parkinson's disease: An Editorial Highlight for 'Deletion of the Vesicular Acetylcholine Transporter from Pedunculopontine/laterodorsal tegmental neurons modifies gait'. Falkenburger B J Neurochem; 2017 Mar; 140(5):688-691. PubMed ID: 28058727 [TBL] [Abstract][Full Text] [Related]
46. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. McKeith I; Del Ser T; Spano P; Emre M; Wesnes K; Anand R; Cicin-Sain A; Ferrara R; Spiegel R Lancet; 2000 Dec; 356(9247):2031-6. PubMed ID: 11145488 [TBL] [Abstract][Full Text] [Related]
47. A randomised controlled trial evaluating the effect of an individual auditory cueing device on freezing and gait speed in people with Parkinson's disease. Ledger S; Galvin R; Lynch D; Stokes EK BMC Neurol; 2008 Dec; 8():46. PubMed ID: 19077238 [TBL] [Abstract][Full Text] [Related]
48. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences. Emre M; Cummings JL; Lane RM J Alzheimers Dis; 2007 Jul; 11(4):509-19. PubMed ID: 17656830 [TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. Wang HF; Yu JT; Tang SW; Jiang T; Tan CC; Meng XF; Wang C; Tan MS; Tan L J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):135-43. PubMed ID: 24828899 [TBL] [Abstract][Full Text] [Related]
50. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Farlow M; Potkin S; Koumaras B; Veach J; Mirski D Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489 [TBL] [Abstract][Full Text] [Related]
51. Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease. Cummings JL J Neurol Neurosurg Psychiatry; 2005 Jul; 76(7):903-4. PubMed ID: 15965192 [No Abstract] [Full Text] [Related]
52. Rehabilitation of older people with Parkinson's disease: an innovative protocol for RCT study to evaluate the potential of robotic-based technologies. Bevilacqua R; Maranesi E; Di Rosa M; Luzi R; Casoni E; Rinaldi N; Baldoni R; Lattanzio F; Di Donna V; Pelliccioni G; Riccardi GR BMC Neurol; 2020 May; 20(1):186. PubMed ID: 32404132 [TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. Rösler M; Anand R; Cicin-Sain A; Gauthier S; Agid Y; Dal-Bianco P; Stähelin HB; Hartman R; Gharabawi M BMJ; 1999 Mar; 318(7184):633-8. PubMed ID: 10066203 [TBL] [Abstract][Full Text] [Related]
56. Risk of falling in Parkinson's disease at the Hoehn-Yahr stage III. Kataoka H; Tanaka N; Eng M; Saeki K; Kiriyama T; Eura N; Ikeda M; Izumi T; Kitauti T; Furiya Y; Sugie K; Ikada Y; Ueno S Eur Neurol; 2011; 66(5):298-304. PubMed ID: 22057308 [TBL] [Abstract][Full Text] [Related]
57. Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial. van der Kolk NM; de Vries NM; Kessels RPC; Joosten H; Zwinderman AH; Post B; Bloem BR Lancet Neurol; 2019 Nov; 18(11):998-1008. PubMed ID: 31521532 [TBL] [Abstract][Full Text] [Related]
58. Effects of rivastigmine on memory and cognition in multiple sclerosis. Shaygannejad V; Janghorbani M; Ashtari F; Zanjani HA; Zakizade N Can J Neurol Sci; 2008 Sep; 35(4):476-81. PubMed ID: 18973065 [TBL] [Abstract][Full Text] [Related]
59. Stepping reaction time and gait adaptability are significantly impaired in people with Parkinson's disease: Implications for fall risk. Caetano MJD; Lord SR; Allen NE; Brodie MA; Song J; Paul SS; Canning CG; Menant JC Parkinsonism Relat Disord; 2018 Feb; 47():32-38. PubMed ID: 29239746 [TBL] [Abstract][Full Text] [Related]
60. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. Ballard C; Margallo-Lana M; Juszczak E; Douglas S; Swann A; Thomas A; O'Brien J; Everratt A; Sadler S; Maddison C; Lee L; Bannister C; Elvish R; Jacoby R BMJ; 2005 Apr; 330(7496):874. PubMed ID: 15722369 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]